RyboDyn Joins Lilly Gateway Labs to Propel Immunotherapy Innovations for Cancer Research
RyboDyn Partners with Lilly Gateway Labs
In an exciting development in biotechnology, RyboDyn, Inc. has announced that they have been selected to join the prestigious Lilly Gateway Labs (LGL) based in San Diego. This partnership provides RyboDyn with unparalleled access to Eli Lilly and Company’s extensive scientific and business networks, marking a significant step forward in the development of next-generation immunotherapies.
The Focus on the Dark Proteome
RyboDyn has been at the forefront of pioneering immunotherapies that target what is known as the dark proteome. This term refers to a previously uncharacterized layer of proteins derived from overlooked RNA species. Through their proprietary sequencing and AI-driven platform, known as RyboCypher™, RyboDyn has identified a novel class of therapeutic targets that are specific to cancer cells. These targets are characterized by their abundant expression on the surface of those cells while being absent in healthy tissues.
The company has recently collaborated with the Moffitt Cancer Center and demonstrated that multiple Dark Targets™ are conserved across a variety of patients. This finding underpins their potential as foundational elements for creating first-in-class precision immunotherapies.
According to Dr. Imad Ajjawi, CEO and Co-founder of RyboDyn, the collaboration with LGL reflects their commitment to translating impactful scientific discoveries into real-world therapies. He emphasized the timeliness of this support from Lilly as they advance their lead programs towards clinical development.
Enhancing Biotech Development Through Collaboration
The residency at LGL is part of the Lilly Catalyze360™ model, a comprehensive strategy aimed at empowering early-stage biotech firms across diverse therapeutic fields. This model connects startups with exceptional lab spaces and a wealth of resources necessary for drug development through its three main areas: Lilly Gateway Labs®, Lilly ExploRD™, and Lilly Ventures.
By securing a spot in Lilly Gateway Labs, situated at the state-of-the-art One Alexandria Square Megacampus in Torrey Pines, RyboDyn is poised to hasten the conversion of its groundbreaking discoveries related to the dark proteome into novel therapeutic solutions. The company is dedicated to not only progressing its drug pipeline toward first-in-human studies but also to establishing strategic collaborations that may bolster its efforts.
The Journey Ahead for RyboDyn
RyboDyn, with its base in San Diego, is positioned to make significant impacts within the biotech field by focusing on first-in-class immunotherapies that harness the power of the dark genome. Utilizing their proprietary RyboCypher™ technology, they are uncovering and validating previously unknown proteins as well as disease-specific therapeutic targets. Their approach adopts a unique "targets-to-assets" model in therapeutic development, making meaningful strides toward addressing unmet medical needs, particularly in cancer treatment.
The company actively collaborates with top clinical institutions, academic researchers, and biopharma partners to enhance the validation and advancement of its drug pipeline. This dedication signifies RyboDyn's commitment to offering transformative solutions for challenging diseases. Later this year, they are expected to unveil new insights that could reshape how immunotherapies are approached in tackling cancer.
Overall, this partnership is not just a milestone for RyboDyn but a hopeful promise of advancements in cancer treatment methodologies through innovative immunotherapy solutions. For further information about RyboDyn and their ongoing initiatives, interested parties can visit their website or contact them directly.